{"Clinical Trial ID": "NCT00553410", "Intervention": ["INTERVENTION 1:", "Bras A: Continuous Letrozole", "- Continuous oil: 5 years continuously (2.5 mg of letrozole per day)", "Letrozole: film-coated tablet, oral administration, 2.5 mg Letrozole per day for 5 years continuously", "INTERVENTION 2:", "Bras B: Intermittent Letrozole", "\u2022 Intermittent oil: 48 months over 5 years: 4 x 9 months (9 months followed by 3 months interval without treatment for 1 to 4 years, -> 36 months) plus 1 x 12 months for 5 years -> 48 months", "\u2022 Letrozole: film-coated tablet, oral administration, 2.5 mg daily, 48 months over 5 years: 4 x 9 months (9 months followed by 3 months interval without treatment for 1 to 4 years, -> 36 months) plus 1 x 12 months for 5 years -> 48 months"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "A confirmed diagnosis of previous non-inflammatory and operational breast cancer that meets the following criteria:", "\u00b7 Positive tumours to steroid hormone receptors (estrogen receptor and/or progesterone receptor), determined by immunohistochemistry, after primary surgery and prior to initiation of prior endocrine treatment", "\u00b7 Pre-local treatment including surgery with or without radiation therapy for primary breast cancer without known loco-regional clinical residual disease", "After primary surgery, eligible patients should have had signs of lymph nodes involvement either in the axillary or internal breast nodes, but not in the supraclavicular lymph nodes.", "Without clinical disease", "Must have completed 4-6 years of selective oestrogen adjuvant (SERM) receptor modulators, aromatase inhibitors (AI) or a sequential combination of both", "When calculating 4-6 years, neoadjuvant endocrine therapy should not be included.", "No signs of recurrent disease or distant metastatic disease", "No prior bilateral breast cancer", "CHARACTERISTICS OF PATIENTS:", "Women", "To be menopausal by one of the following criteria:", "Patients of any age with bilateral oophorectomy (including radiation castration AND amenorrhoea for > 3 months)", "Patients aged 56 years or older with any evidence of ovarian function should have biochemical evidence of a specific postmenopausal state (defined as estradiol, luteinizing hormone [LH] and follicle-stimulating hormone [FSH] in the postmenopausal interval)", "Patients 55 years of age or younger must present biochemical evidence of a specific postmenopausal state (defined as estradiol, LH, and FSH in the postmenopausal interval)", "Patients who have received luteinizing hormone (HDHL) release analogues in the past year are eligible if they have accurate evidence of their postmenopausal status as defined above.", "Clinically adequate liver function", "No bone fracture due to osteoporosis at any time during the previous 4-6 years of treatment", "No prior or present malignancy except a sufficiently treated basal or squamous carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or ipsilateral breast carcinoma in situ", "No other non-malignant systemic disease (cardiovascular, renal, pulmonary, etc.) that would prevent prolonged follow-up", "No psychiatric, addictive or other disorders that compromise compliance with protocol requirements", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics", "More than 12 months since previous treatment and no other concomitant endocrine SERM/AI treatment", "Any type of previously authorised adjuvant treatment, including, but not limited to, one of the following:", "Neoadjuvant chemotherapy", "Endocrine neoadjuvant treatment", "- Adjuvant chemotherapy", "- Trastuzumab (Herceptin\u00ae)", "Ovarian ablation", "Gonadotropin releasing hormonal analogues", "Lapatinib ditosylate", "No concomitant hormone replacement therapy, no bisphosphonates (except for bone loss treatment), or any other research agent"], "Results": ["Performance measures:", "\u2022 Disease-free survival (DFS)", "The duration of the period from randomization to the first indication of the following events: invasive recurrence at the local level (including limited recurrence after breast conservation treatment), regional or remote sites; new invasive cancer in the contralateral breast; any second invasive malignancy (non-brassial); or death without previous cancer event.", "Time frame: Estimated at 5 years, compared to a median follow-up of 60 months", "Results 1:", "Title of the arm/group: Arm A: Letrozole continu", "Description of the arm/group: Continuous oil: 5 years continuously (2.5 mg of Letrozole per day)", "Letrozole: film-coated tablet, oral administration, 2.5 mg Letrozole per day for 5 years continuously", "Total number of participants analysed: 2426", "Type of measurement: Number", "Unit of measure: percentage of patients 87.5 (86-88.8)", "Results 2:", "Title of arm/group: Arm B: Intermittent Letrozole", "Description of the arm/group: Intermittent oil: 48 months over 5 years: 4 x 9 months (9 months followed by 3 months interval without treatment for 1 to 4 years, -> 36 months) plus 1 x 12 months for 5 years -> 48 months", "\u2022 Letrozole: film-coated tablet, oral administration, 2.5 mg daily, 48 months over 5 years: 4 x 9 months (9 months followed by 3 months interval without treatment for 1 to 4 years, -> 36 months) plus 1 x 12 months for 5 years -> 48 months", "Total number of participants analysed: 2425", "Type of measurement: Number", "Unit of measure: percentage of patients 85.8 (84.2 to 87.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 1004/2411 (41.64 per cent)", "Hemoglobin 1/2411 (0.04%)", "Arrhythmia - Other (specify) 2/2411 (0.08%)", "- Heart ischaemia/infarction 21/2411 (0.87%)", "Atrio-ventricular conduction/heart block abnormality - Mobitz Type I AV-2 Block (Wenckebach) 0/2411 (0.00 %)", "Atrioventricular conduction/heart block abnormality - AV-third degree block (full AV block) 2/2411 (0.08%)", "Adverse Events 2:", "Total: 1052/2417 (43.53 per cent)", "Hemoglobin 1/2417 (0.04%)", "Arrhythmia - Other (specify) 2/2417 (0.08%)", "- Cardiac ischemia/infarction 22/2417 (0.91%)", "Atrioventricular conduction/heart block abnormality - Mobitz Type I AV-2 (Wenckebach) 2/2417 (0.08%)", "Atrioventricular conduction/heart block abnormality - AV-third degree block (full AV block) 0/2417 (0.00%)"]}